Navigation Links
Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease
Date:5/20/2008

Data on Newly-Approved Cimzia(R) Presented at Digestive Disease Week (DDW)

SAN DIEGO, May 20 /PRNewswire/ -- UCB announced today that data presented at Digestive Disease Week reaffirm the long-term, sustainable efficacy and safety of Cimzia(R) (certolizumab pegol) at stable doses in treating patients with moderate to severe Crohn's disease. Data also showed continued remission amongst the majority of responders and the remission rate remained stable in many of the patients who were re-induced with Cimzia(R). These results represent data from the PRECiSE trial program, which evaluated more than 1,300 patients receiving continuous treatment with Cimzia(R) (400 mg) for up to 18 months.

"The long-term Cimzia(R) data provide very important information for clinical practitioners treating people with Crohn's disease," said study investigator Gary R. Lichtenstein, M.D., professor of medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa. "In clinical trials, Cimzia(R) showed remarkable and sustainable long-term results without the need for dose escalation. Further, patients can achieve long-term symptom relief and remission regardless of the magnitude and rapidity of onset of the initial response."

Cimzia(R) is the first and only PEGylated anti-TNF (Tumor Necrosis Factor alpha) antibody approved for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) was approved by the U.S. Food and Drug Administration (FDA) on April 22, 2008.

UCB, the manufacturer of Cimzia(R), presented analyses of the PRECiSE 3 and 4 open-label extension studies, which demonstrated the long-term efficacy of Cimzia(R) in treating Crohn's disease. PRECiSE 3 data showed that eight out of ten patients who were in remission at six months stayed in remission for up to 18 months. Furthermore, 35 percent of pat
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
3. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
4. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
5. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
6. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
7. Gene Therapy Provides Vision to People who Were Nearly Blind
8. Arpida Provides Further Comments on the Pivotal Phase III Trials
9. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
10. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
11. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Capnia, Inc. (NASDAQ: ... medical diagnostics based on its proprietary Sensalyze™ Technology ... announced financial results for the third quarter and ... "Following the completion of our initial public offering ... the recently initiated CoSense® commercial launch," said Anish ...
(Date:12/19/2014)... -- Baptist Health Lexington is the first facility in ... Fibrillation with Electrophysiology Services (EPS) Accreditation status from the Society ... the most common cardiac arrhythmia and has become recognized as ... stroke and possible death. More than 5 million patients in ... and the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... 2014 As testosterone therapy lawsuit ... stroke and blood clots from using testosterone products such ... study shows that the male hormone testosterone may increase ... study published in the Proceedings of the National Academy ... a group of male rats with naturally occurring colon ...
(Date:12/20/2014)... BambooIndustry.com is a leading eco-friendly ... announced its bamboo flooring promotion for the coming ... certified suppliers, and offers the best bamboo products ... current promotion, all customers can enjoy a special ... they know BambooIndustry.com from press releases. , The ...
(Date:12/20/2014)... 2014 DePuy Pinnacle hip lawsuits ... of the artificial hip system was defectively designed ... courts, Bernstein Liebhard LLP reports. According to an ... Court on December 2nd, counsel in 10 DePuy ... plaintiffs on November 19, 2014, with depositions to ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer ... dress fans. The company has recently updated its official ... the holiday season, Angeldress Blog has recommended ... , Angeldress.co.uk prides itself in offering a huge selection ... All the company’s outfits are very carefully selected based ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... , SUNDAY, Dec. 6 (HealthDay News) -- Early roots of the ... lived thousands or millions of years ago, new research suggests. ... tiger,s genetic material, scientists say, and a remnant of that cat ... may have bitten a monkey, setting off an evolution of the ...
... Dec. 6 Sickle cell disease, a condition characterized by ... most common genetic blood disorders affecting millions of people around ... at the 51st Annual Meeting of the American Society of ... H1N1 pandemic presents for children with this blood disorder, evaluations ...
... ... information and Treatment site www.sleeping-with-a-sleeping-disorder.com is asking people ,who have ... world to donate their best ,insomnia remedies for a good cause. The ... ,Encyclopedia, by YOU, to be sold from the website in early January ...
... phase 1/2 clinical trial that it is a "highly ... multiple myeloma, a cancer of white blood cells in bone ... or better were seen in all of the 66 patients ... 74 percent having a "very good partial response rate" in ...
... , ... The first Football,for Hope Centre in Khayelitsha in the outskirts of ... S. Blatter was joined by,Western Cape Premier Helen Zille, 2010 FIFA ... Football Association,President Kirsten Nematandani and Executive Mayor of the City of ...
... triggers, experts advise , SATURDAY, Dec. 5 (HealthDay News) ... asthma can have bad reactions to certain holiday traditions ... and wheezing, according to the American College of Allergy, ... to live evergreens may choose to decorate with artificial ...
Cached Medicine News:Health News:AIDS May Date Back to Ancient Tiger 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3Health News:Keep Asthma, Allergies at Bay for the Holidays 2
Soft red rubber. Adjustable flange. Pediatric sizes available....
Smooth flexible medical grade white low density polyethylene with reinforced block to prevent collapse....
Two-channel, Berman design. Semirigid, nontoxic polyethylene. Individually packaged, 48 per case. Latex Free....
Guedel-style enclosed center channel. Semirigid, nontoxic polyethylene with color-coded bite block. Individually packaged, 48 per case. Latex Free....
Medicine Products: